Article citationsMore>>

Mok, T., Camidge, D.R., Gadgeel, S.M., Rosell, R., Dziadziuszko, R., et al. (2020) Updated Overall Survival and Final Progression-Free Survival Data for Patients with Treatment-Naive Advanced ALK-Positive Non-Small-Cell Lung Cancer in the ALEX Study. Annals of Oncology, 31, 1056-1064.
https://doi.org/10.1016/j.annonc.2020.04.478

has been cited by the following article:

• TITLE: Alectinib-Induced Immune Hemolytic Anemia in a Patient with Lung Adenocarcinoma: Case Report and Literature Review

  AUTHORS: Chai Young Lee, Yon Ju Ryu

  KEYWORDS: Non-Small Cell Lung Cancer, Alectinib, Brigatinib, Hemolytic Anemia, Drug-Induced Hemolytic Anemia

  JOURNAL NAME: Case Reports in Clinical Medicine, Vol.13 No.8, August 28, 2024

  ABSTRACT: Alectinib is a selective Anaplastic Lymphoma Kinase (ALK) tyrosine kinase inhibitor used as standard therapy for ALK-rearranged lung adenocarcinoma. Hemolytic anemia is considered a rare but significant adverse event of alectinib. Here, we report the case of a 78-year-old female with advanced ALK rearrangement-positive lung adenocarcinoma who developed grade 4 drug-induced hemolytic anemia after receiving alectinib as first-line therapy. We discontinued alectinib treatment and switched to brigatinib. As a result, anemia improved without recurrence of lung adenocarcinoma over one year.